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ABSTRACT
Background: BCG and measles vaccine (MV) may
have beneficial non-specific effects (NSEs). If an
unplanned intervention with a vaccine (a natural
experiment) modifies the estimated effect in a
randomised controlled trial (RCT), this suggests NSEs.
We used this approach to test NSEs of triple oral polio
vaccine (OPV).
Methods: During an RCT of 2 doses of MV at 4.5 and
9 months versus 1 dose of MV at 9 months of age, we
experienced 2 natural experiments with OPV. We
assessed whether these OPV experiments modified the
effect of 2-dose MV in the MV trial.
Setting: MV RCT conducted in urban Guinea-Bissau
2003–2009.
Interventions: Natural experiments with OPV due to
missing vaccine and the implementation of OPV
campaigns.
Main outcome measure: Changes in the mortality
rate ratio (MRR) for 2-dose MV versus 1-dose MV.
Results: First, the MRR (2-dose/1-dose MV) overall
was 0.70 (0.52 to 0.94), but the MRR was 1.04 (0.53
to 2.04) when OPV at birth (OPV0) was not given,
suggesting that early priming with OPV was important
for the effect of 2-dose MV. The effect of OPV0
depended on age of administration; the MRR (2-dose/
1-dose MV) was 0.45 (0.29 to 0.71) for children
receiving OPV0 in the first week of life, but 3.63 (0.87
to 15.2) for those receiving OPV0 after the first month
of life (p=0.007, test of no interaction). Second,
campaign-OPV may have reduced the difference
between the randomisation groups since the MRR (2-
dose/1-dose MV) was 0.60 (0.42 to 0.85) for children
who had not received campaign-OPV before RCT-
enrolment versus 0.72 (0.23 to 2.31) and 1.42 (0.70 to
2.90) for children who had received 1 or 2 doses of
campaign-OPV-before-enrolment, respectively.
Conclusions: Bissau had no polio infection during
this trial, so OPV0 and campaign-OPV may have NSEs
since they modified the effect of 2-dose MV in an RCT.
Different interventions may interact to a much larger
effect than usually assumed.
INTRODUCTION
The WHO’s Strategic Advisory Group of
Experts (SAGE) on immunisation recently
conducted a review of the potential non-
speciﬁc effects of BCG, diphtheria-tetanus-
pertussis (DTP) and measles vaccine (MV).
The review concluded that BCG and MV
approximately halved the mortality risk.1 2
The studies of MV in which measles infection
or measles deaths were censored in the sur-
vival analyses3–5 suggest that the effects of
MV on mortality are not fully explained by
the prevention of measles infection.
Likewise, there was no indication that preven-
tion of tuberculosis (TB) explained the
beneﬁcial effect of BCG vaccination.1 Hence,
these two vaccines may have NSEs. Several
immunological studies supports that vaccines
Strengths and limitations of this study
▪ This is one of the first studies to examine
whether oral polio vaccine (OPV) has an effect
on child survival and whether OPV interacts with
other interventions.
▪ We analysed whether two natural experiments
with OPV at birth and OPV campaigns taking
place during a trial of two doses of measles
vaccine (MV) at 4.5 and 9 months compared
with one dose of MV at 9 months of age affected
the overall outcome in the trial.
▪ The natural experiments were observational but
control for background factors which varied
between groups being compared in the trial did
not modify the results.
▪ There has been no polio infection in
Guinea-Bissau during the study period, and
since OPV modified the effect of the specific MV
interventions, OPV may have non-specific
effects.
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can induce non-speciﬁc or heterologous effects by indu-
cing cross-reactive T-cells or by training of innate
immunity.6 7 Hence, we need to examine the potential
NSEs of other routine vaccines than those initially
reviewed by SAGE.
We have therefore examined the potential NSEs of
oral polio vaccine (OPV).8–10 Investigations of NSEs of
routine vaccines are complex because it is usually not
possible to randomise children to vaccines already
recommended if it means that the vaccine is withheld or
delayed for some children. OPV is additionally difﬁcult
to study because it is routinely given together with DTP
in three doses in the ﬁrst months of life, and it is there-
fore nearly impossible to assess the separate effects of
OPV. Hence, ‘natural experiments’ where the national
immunisation programme are missing vaccine or imple-
ment a new vaccine campaign are useful to assess the
effect of OPV.8 9
Vaccine randomised controlled trials (RCTs) with
focus on NSEs examine whether the study vaccine modi-
ﬁes susceptibility to unrelated infections with implica-
tions for mortality.3 10 If another vaccine given in both
intervention groups has NSEs, it is likely to alter the dif-
ference between the randomisation groups within the
RCT. A potential way to assess NSEs therefore arises if a
natural experiment with a vaccine occurs during the
conduct of a vaccine RCT. It is then possible to assess if
the estimated effect of the RCT vaccine changes as a
result of the natural experiments. If that happens, it
would be evidence of NSEs of the natural experiment
vaccine.
We used this approach in connection with an RCT of
two doses of MV at 4.5 and 9 months versus one dose of
MV at 9 months of age (ﬁgure 1). We experienced two
natural experiments with OPV during the trial: (1) OPV
at birth (OPV0) was not provided during several
months; and (2) additional doses of OPV were adminis-
tered in several national OPV campaigns (ﬁgure 2).
METHODS
Two-dose MV trial
The two-dose MV trial recruited children between 2003
and 2007 and followed the children to 36 months of age
in an urban area in Guinea-Bissau, which has been fol-
lowed with a Health and Demographic Surveillance
System (HDSS) since 1978.3 The two-dose MV trial
design and randomisation procedures have been
described in detail elsewhere.3 Brieﬂy, at 4.5 months of
age, 6417 children, who had received all three doses of
DTP recommended at 6, 10 and 14 weeks of age, were
randomised 1:2 to receive standard dose Edmonston-
Zagreb (EZ) MV at enrolment or no vaccine. At
9 months of age, all children were invited back to
receive the standard MV recommended by the WHO.
The two-dose group received EZ MV; the one-dose
group had been randomised at 4.5 months to receive
either EZ or Schwarz MV at 9 months of age. Hence,
between 4.5 and 9 months of age, the trial compared
the effect on mortality of one early dose of MV versus
no MV (ie, having the third doses of DTP and OPV as
the most recent vaccination); between 9 and 36 months
of age, the trial compared two doses of MV versus one
dose of MV (ﬁgure 1). The project registered all routine
vaccines that the children had received.
The results of the two-dose MV trial on child mortality
between 4.5 and 36 months of age were published in
2010.3 The main analysis was based on 6417 participants.
The majority of children in the MV trial3 had taken part
in trials of neonatal vitamin A supplementation
(NVAS)11 and since NVAS is not ofﬁcial policy and is
unlikely to become policy,12 we tested the effect of two
doses of MV for the 3402 children who had not received
NVAS.
Figure 1 Design of the two-dose versus one-dose MV
randomised controlled trial. DTP, diphtheria-tetanus-pertussis;
OPV, oral polio vaccine; mo, month; MV, measles vaccine.
Figure 2 Events during this study. Enrolment took place between 2003 and 2007. In 2004 and 2005, there were two oral polio
vaccine (OPV) campaigns with a 1 month interval. In the first campaign, campaign-OPV (OPVc) was given to all children aged
0–59 months and in the second campaign OPVc was given to the same age group together with vitamin A supplementation
(VAS) to children aged 6–59 months. During 2004, there were two periods, marked with a solid black line, in which children did
not received OPV at birth (OPV0).
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Natural experiment I: missing OPV0 in 2004. Nearly all
children in the two-dose MV trial received BCG at birth
or shortly thereafter. More than 80% of the children
enrolled in the two-dose MV trial had previously taken
part in trials3 in which the dates of BCG and OPV vacci-
nations after birth were documented. OPV was missing
in Guinea-Bissau for several months in 2004 (ﬁgure 2)
and many children did therefore not receive OPV0.13
Whether the children had received OPV0 or not was
registered as part of these trials in which the date of
BCG and OPV vaccinations was noted. We examined
whether receiving OPV0 and the age at which BCG and
OPV0 was given modiﬁed the effect of a two-dose versus
one-dose MV in the RCT.
Natural experiment II: OPV campaigns in 2004 and 2005.
There were two national campaigns with trivalent OPV
with 1 month’s interval in 2004 and in 2005 (see
ﬁgure 2). In both years, OPV was ﬁrst provided alone,
and then 1 month later OPV was administered together
with vitamin A supplementation (VAS). OPV was pro-
vided to all children between birth and 5 years of age,
whereas VAS was only administered to children who
were 6 months and older. In 2004, the campaigns took
place in the end of October (OPV only) and November
(OPV+VAS); in 2005, campaigns were in November
(OPV only) and December (OPV+VAS).
The OPV campaigns were conducted by staff from the
three health centres in the study area. They went from
house to house. The nurses were accompanied by
trained HDSS ﬁeldworkers who had lists of all children
in the study area generated from the HDSS database.
Fieldworkers were followed by a supervisor for at least
1 day during the 4-day long campaigns. The ﬁeldworkers
registered the presence of the children, and whether
they received OPV (and VAS) on that day, or whether
they had received it elsewhere.
Patient involvement
The timing of the campaigns was decided by national
public health authorities. The authors decided after the
campaigns had occurred to examine whether the cam-
paigns had an impact on the RCT. Hence, guardians of
patients were not involved in the planning of the study.
The results will be disseminated to the general public
through medical journals and speciﬁcally to the WHO,
which determines global vaccination policies, and to the
Ministry of Health if there is scientiﬁc evidence to
support a change in policy or practice.
Statistical methods
We used the previously presented RCT data set to
compare mortality of children randomised to two doses
of MV at 4.5 and 9 months or one dose of MV at
9 months of age, providing mortality rate ratios (MRRs)
(two-dose/one-dose MV) from 4.5 months to 36 months
of age.3 We conducted all analyses including all 6417 chil-
dren, and also conducted all analyses in the subgroup of
3402 children who had not received NVAS at birth. The
conclusions with respect to OPV were essentially similar,
and therefore only the overall results are presented.
The original analysis stratiﬁed for the health centre
area (N=3) but did not adjust for background factors
since this was a randomised trial and the background
factors were balanced between the two randomisation
groups (3, table 1). Since the key point of the present
analysis is to see whether the campaigns changed the
effect measured in the RCT, we are not adjusting for
other background factors in the main analyses. However,
since the allocation to the subgroups in the two natural
experiments could have been inﬂuenced by background
factors, we analysed the distribution of background
factors in both experiments (see online supplementary
tables S1 and S2) and present analyses where we
Table 1 The mortality rates and mortality rate ratio (MRR) of recipients of two-dose MV compared with one-dose MV in
relation to the timing of OPV at birth (OPV0)
Mortality rates (deaths/person-days) (N)
Timing of administration
of OPV0 Early 2-dose group 1-dose group
MRR (2-dose/1-dose
MV) (95% CI)
P for trend
with age*
All children (main result of
trial)
N=6417
1.23 (58/1 722 488) (2129) 1.79 (159/3 248 194) (4288) 0.70 (0.52 to 0.94)
BCG, no OPV0 2.11 (13/224 878) (284) 2.04 (24/428 825) (570) 1.04 (0.53 to 2.04)
BCG+OPV0 provided
Days 0–7
0.78 (23/1 077 329) (1317) 1.75 (96/2 008 964) (2661) 0.45 (0.29 to 0.71) p=0.02
BCG+OPV0 provided
Days 8–14
1.48 (9/222 825) (277) 1.91 (21/400 594) (523) 0.78 (0.36 to 1.70)
BCG+OPV0 provided
Days 15–30
2.23 (8/130 828) (165) 2.06 (15/266 452) (349) 1.10 (0.47 to 2.59)
BCG+OPV0 provided
Days 31+
2.74 (5/66 628) (86) 0.76 (3/143 359) (185) 3.63 (0.87 to 15.2)
Notes: The estimates are based on a Cox proportional hazards model; to be precise, we have reported person-days and not person-years.
*The age trend tested for a significant linear increase in the effect across the four groups.
MV, measles vaccine; OPV, oral polio vaccine; OPV0, OPV at birth.
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adjusted for background factors which differed signiﬁ-
cantly at the time of group allocation or before (see
online supplementary tables S3 and S4).
Natural experiment I: missing OPV0. We ﬁrst examined
whether the MRR (two-dose/one-dose MV) was different
in children who received or did not receive OPV0. We
have found in an RCT that early administration of OPV
gave a stronger beneﬁcial effect,10 and we therefore also
assessed whether the age of administration of OPV0 and
BCG had a modifying effect.
Natural experiment II: campaign-OPV. In the analysis of
campaign-OPV, we examined whether the MRR
(two-dose/one-dose MV) was different depending on
whether the children had received campaign-OPV or
not before enrolment in the trial. Thus, we calculated
the MRR (two-dose/one-dose MV) separately for chil-
dren who received campaign-OPV-before-enrolment in
the trial (not given with VAS, which was only given after
6 months of age), and for those who did not receive
campaign-OPV-before-enrolment. Of the 1380 children
receiving campaign-OPV-before-enrolment, only 2%
(N=25) had received OPV with VAS; we are only showing
the results for all children since excluding the 25 chil-
dren who got VAS with OPV did not change the results.
We also assessed if campaign-OPV-after-enrolment in
the trial (usually given with VAS) modiﬁed the MRR
(two-dose/one-dose MV). Since nearly all children
receive campaign-OPV and we would not be able to
document that absent and travelling older children had
received campaign-OPV, this analysis was based on the
assumption that all children still living in the community
got the campaign-OPV on the ﬁrst day of the campaign.
During the conduct of the present RCT, there was a
national MV campaign (5/2006). The children in the
two-dose trial were exempted from taking part in the
MV campaign.3 In addition, there were national VAS
campaigns in November 2003, and VAS and mebenda-
zole campaigns in May and December 2006, July and
December 2007, July 2008, and January and July of
2009. These VAS campaigns did not affect the
mortality rate within the MV trial; the mortality rate
after VAS campaigns versus before VAS campaigns was
0.92 (0.63 to 1.35).
Outcome measures and models: We present deaths and
observation time together with MRR (two-dose/
one-dose MV) from a Cox model with age as the under-
lying time scale and stratiﬁed by district as in the ori-
ginal analysis.3 The model assumptions were assessed
graphically and tested using Schoenfeld residuals. Since
mortality levels could have changed over time, we also
conducted the analyses with calendar time as the under-
lying time scale adjusting for age as a linear predictor.
Results were essentially similar, not changing any of the
estimates by more than ‘0.02’. Thus, we only show
results from the analyses with age as the underlying time
scale. To test for no interaction, we compared the effect
of two-dose vs one-dose MV in strata of the suspected
effect modiﬁer using Wald statistics.
RESULTS
The two-dose MV trial of child mortality between 4.5
and 36 months of age included 6417 participants in the
main analysis. Background factors were equally distribu-
ted between the two randomisation groups (3, table 1).
In the survival analysis, the children were followed until
they moved out of the area, died or attained 3 years of
age, whichever came ﬁrst. As described previously, the
per-protocol MRR (two-dose/one-dose MV) between 4.5
and 36 months for children who did get two doses of
MV was 0.70 (0.52 to 0.94).3 We have used the per-
protocol data set for the main analyses in the present
paper but results for the intention-to-treat data set are
presented in online supplementary tables S5 and S6.
Natural experiment I: missing OPV0
All 6417 children in the trial were included in the ana-
lysis; 854 (13%) did not receive OPV0 (table 1). For chil-
dren who had not received OPV0, the MRR (two-dose/
one-dose MV) was 1.04 (0.53 to 2.04) (table 1, ﬁgure 3).
The beneﬁcial effect of two-dose MV increased the
earlier OPV0 and BCG had been given; the MRR was
0.45 (0.29 to 0.71) for children receiving OPV0 in the
ﬁrst week of life but 3.63 (0.87 to 15.2) for those receiv-
ing OPV0 after the ﬁrst month of life (p=0.007, test of
no interaction). The trend for increasing beneﬁt of
two-dose MV with earlier OPV0 administration was given
was statistically signiﬁcant (p=0.02) (table 1). If age at
OPV0 was analysed as a continuous variable, the MRR
(two-dose/one-dose MV) was reduced by 4% (1–6%) for
each additional day of age at OPV0 vaccination. There
were minor but statistically signiﬁcant differences in sex
distribution and mother’s mid-upper arm circumference
(MUAC) between those who received OPV0 and those
who did not (see online supplementary table S1); adjust-
ment for these factors did not modify the results (see
online supplementary table S3).
Results were essentially similar in the intention-to-treat
analysis (see online supplementary table S5).
Natural experiment II: campaign-OPV
Campaign-OPV-before-enrolment: All 6417 children in the
trial were included in the analysis. The proportion of
children who had received campaign-OPV prior to
enrolment was similar in the two-dose (21.5% (458/
2129)) and one-dose (21.3% (912/4288)) groups.
Among the children who were or became participants in
the RCT and lived in the community in 2004 and 2005,
92% (2319/2512) and 87% (3599/4123) were registered
to have received at least one campaign-OPV, respectively.
Among children who had not received any campaign-
OPV-before-enrolment, the MRR (two-dose/one-dose
MV) was 0.60 (0.42 to 0.85), whereas the MRR
(two-dose/one-dose MV) was 1.16 (0.64 to 2.12) for
those who received campaign-OPV-before-enrolment
(p=0.06, test of no interaction) (table 2). If two doses of
campaign-OPV had been received before enrolment,
the MRR (two-dose/one-dose MV) was 1.42 (0.70 to
4 Aaby P, et al. BMJ Open 2016;6:e013335. doi:10.1136/bmjopen-2016-013335
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2.90), signiﬁcantly different from the effect among chil-
dren receiving no campaign-OPV-before-enrolment
(p=0.03, test of no interaction) (table 2). The analyses
gave similar results for boys and girls (data not shown).
There were minor but statistically signiﬁcant differ-
ences in the number of persons sleeping per room and
mother’s MUAC between those who received
campaign-OPV-before-enrolment and those who did not
(see online supplementary table S2); adjustment for
these factors did not modify the results (see online
supplementary table S4).
Results were essentially similar in the intention-to-treat
analysis (see online supplementary table S6).
Campaign-OPV-after-enrolment: In the group which did
not receive campaign-OPV-before-enrolment and did
not receive or had not yet received campaign-
OPV-after-enrolment, early two-dose MV was associated
with a beneﬁcial effect the MMR being 0.53 (0.32 to
0.87) (table 3); the effect was similar for boys and girls
(data not shown). For children who had received
campaign-OPV-after-enrolment, the MRR (two-dose
MV/one-dose MV) was signiﬁcantly better for girls than
for boys (p=0.05, test of no interaction). The effect of
campaign-OPV-after-enrolment on the MRR (two-dose
MV/one-dose MV) differed signiﬁcantly for the children
who had (MRR=2.90 (0.82 to 10.3)) and had not
received campaign-OPV-before-enrolment (MRR=0.68
(0.41 to 1.12)) (p=0.04, test of no interaction) (table 3).
DISCUSSION
Main observations: OPV administered as either OPV0 or
campaign-OPV had NSEs because it changed the MRRs
(two-dose MV/one-dose MV) in the RCT. First, the bene-
ﬁcial effect of early MV administered at 4.5 months of
age depended on early priming with OPV0. Second, the
Figure 3 The mortality rates and MRR for recipients of two-dose MV compared with one dose MV in relation to the timing of
OPV at birth. MRR, mortality rate ratio; MV, measles vaccine; OPV, oral polio vaccine; OPV0, OPV at birth.
Table 2 The mortality rates and mortality rate ratio (MRR) of recipients of two-dose MV compared with one-dose MV in
relation to the administration of campaign-OPV-before-enrolment, overall and by number of doses
Mortality rates (deaths/person-days) MRR (2-dose/1-dose MV)
(95% CI)Early 2-dose group 1-dose group
No campaign-OPV-before-enrolment 1.11 (41/1 354 117) 1.88 (131/2 542 844) 0.60 (0.42 to 0.85)*
Campaign-OPV-before-enrolment 1.69 (17/368 371) 1.45 (28/705 350) 1.16 (0.64 to 2.13)*
1-dose OPV 1.23 (4/118 730) 1.68 (10/217 279) 0.72 (0.23 to 2.31)
2-dose OPV 1.90 (13/249 641) 1.35 (18/488 071) 1.42 (0.70 to 2.90)
Notes: The estimates are based on a Cox proportional hazards model; to be precise, we have reported person-days and not person-years.
*Test for whether the effect of early two-dose MV is equal in those receiving no campaign-OPV-before-enrolment and those receiving
campaign-OPV-before-enrolment, p=0.06.
MV, measles vaccine; OPV, oral polio vaccine.
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beneﬁcial effect of early MV was strongest when the chil-
dren had not received campaign-OPV before or after
enrolment in the trial.
Strengths and weaknesses: Although the present study was
not a planned study, its design limited the possibility of
uncontrolled confounding because all children were
enrolled in the two-dose MV trial, which used the same
inclusion criteria throughout. The unavailability of
OPV0 and the availability of OPV campaigns were
natural experiments not dependent on the health status
of the children.
The mortality rate between 4.5 and 36 months was sig-
niﬁcantly lower the earlier OPV0 (and BCG) had been
given. The timing of OPV0 could have depended on the
health status and the socioeconomic conditions of the
child. For example, the best families or healthiest chil-
dren might be delivered at the maternity ward or come
ﬁrst for vaccination at a health centre. Alternatively, sick
and disadvantaged children may have been brought later
for vaccination. However, such confounding would not
explain why two doses of MV had the best effect among
those vaccinated with OPV0 in the ﬁrst week of life, as
children from the best families presumably have the least
to gain. Furthermore, we found in an RCT of OPV0 that
the effect was considerably stronger when the OPV0 had
been given within the ﬁrst 2 days of life.10 The observa-
tion therefore suggests that OPV0 primes the immune
system in ways which are subsequently enhanced by early
MV at 4–5 months of age.
It should be noted, however, that the period during
2004 with missing OPV0 has previously produced the
unexpected result that male infant mortality was lower
in neonates who had not received OPV0 than in neo-
nates who had received OPV0.13 This ﬁnding was contra-
dicted in a subsequent RCT.10 The unexpected result
may have been due partly to the 2004-OPV campaigns
coming just after the period with missing OPV0, which
lowered the general mortality rate and had a particularly
beneﬁcial effect for males (submitted).
The main potential confounding factor for the effect
of campaign-OPV would be a change in mortality rate
coinciding with the timing of the OPV campaigns.
However, adjustment for calendar time had no impact
on the estimates. The study had limited power to analyse
the interactions between trial randomisation and the
many combinations of campaign-OPV before and after
enrolment (tables 2 and 3).
Single intervention paradigm: In the current epidemiology
culture, an RCT measures the effect of an intervention
in a controlled situation, that is, other interventions are
not tested at the same time. Hence, the effect measured
in the RCT is believed to be the ‘true’ effect. If the inter-
vention becomes policy, it will be assumed in future
modelling of programme impact that this ‘true’ effect
will continue. For example, high-dose VAS was tested in
eight trials in the 1980s and early 1990s and found to
reduce mortality by 23–30% in two meta-analyses. This
effect is still assumed to exist,14 even though the only
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two recent trials contradict the assumption.15 16 There
are similar conﬂicting stories for other interventions
including neonatal vitamin A (NVAS)12 17 18 and MV.19
There are probably several causes of these conﬂicting
stories, but a main reason is the disease-speciﬁc perspec-
tive underlying preventive global childcare programmes.
It is usually assumed that interventions have only one
speciﬁc effect on the immune system preventing a spe-
ciﬁc disease or deﬁciency. However, a growing number
of studies show that interventions may have much wider
effects by reprogramming the immune system to
enhanced protection or susceptibility to unrelated infec-
tions.6 7 From this perspective, the ‘true’ effect of an
intervention is the measured reduction in overall mortal-
ity/morbidity under a certain set of speciﬁed conditions
in relation to other interventions affecting mortality. For
example, the optimal effect of early MV at 4.5 months of
age was obtained when children were primed with OPV0
(and BCG) in the ﬁrst weeks of life (this study), did not
receive NVAS,3 did not receive campaign-OPV before
(this study), did not receive DTP after early MV3 and
did receive MV in the presence of maternal antibodies.20
When altering these conditions, and other potential
priming conditions that we do not know about yet, the
‘true’ effect is no longer observed. However, departures
from the expected effects may be a fruitful instrument
for accumulating new knowledge about the limits or
conditions under which an intervention will work or
have deleterious effects.
Consistency or contradiction with previous observations: Our
ﬁnding that OPV has NSEs is supported in the literature.
Earlier studies from the 1960s when OPV was developed
reported that OPV reduced diarrhoeal mortality in Chile
and Brazil and Russian researchers claimed more
general effects on health including reducing respiratory
infection from stimulation with non-pathogenic entero-
virus including OPV.21–23 These observations23 were not
pursued outside the Soviet Union.
When the ﬁrst OPV campaigns were implemented in
Guinea-Bissau in 1998, we examined the effect on child
survival of having participated versus not having partici-
pated in the campaign.9 OPV apparently had a beneﬁ-
cial effect for the youngest children <6 months of age;
for older children, it was difﬁcult to determine a separ-
ate effect due to the strongly beneﬁcial effect of MV. We
have also found in a natural experiment, when DTP was
missing, that the case fatality at the hospital was much
lower for children who had received OPV only and not
OPV+DTP as currently recommended.8
We have also conducted two RCTs of OPV0 in Bissau;
in one trial, OPV0 was compared with neonatal VAS
among low birthweight boys who normally do not
receive BCG at birth, and in another RCT BCG+OPV0
was compared with BCG only among normal birthweight
children. OPV0 was associated with 32% lower infant
mortality in both trials, an effect which was statistically
signiﬁcant in the larger trial among normal birthweight
children.10 24
Studies from high income countries have likewise sug-
gested that OPV may have beneﬁcial NSEs. In Finland,
children who received OPV in a trial had fewer episodes
of otitis media at age 6–18 months than control children
who received inactivated polio vaccine (IPV).25 In a
nationwide study in Denmark, the routine OPV which
used to be given at 2 years of age (until 2001) was asso-
ciated with a 15% (5–23%) reduction in the risk of hos-
pital admissions compared with children who had
acellular DTP, Haemophilus inﬂuenzae type b and inac-
tivated polio vaccine (DTaP-Hib-IPV) as their most
recent vaccination, most of the effect coming from pre-
vention of admissions for lower respiratory infections.26
The effect of OPV was similar to the effect of MMR.27 In
Denmark, a second and third dose of OPV was recom-
mended at 3 and 4 years of age. These additional doses
were associated with signiﬁcant reductions in
admissions.
Interpretation: OPV produced different NSEs in this study
and we have tried to summarise these in table 4.28–31
Apparently, OPV given early in life provided priming
which subsequently enhanced the beneﬁcial effects of
early MV. In our RCT of OPV0+BCG versus BCG only,
the effect on infant mortality was particularly strong
when OPV0 was given in the ﬁrst days of life.10 Studies
of BCG have likewise indicated that the beneﬁcial effect
is particularly good when administered early.32 Although
the effect in the present analysis is different since it is
generated by a subsequent early MV, it does suggest that
OPV0 is capable of inducing strong immune training. It
is known that other live vaccines may induce an immune
training effect which reduces susceptibility to unrelated
infections. For example, BCG reprogrammes monocytes
through epigenetic changes to a more proinﬂammatory
response; in animal models, this response reduces mor-
tality from challenge to unrelated infections.7 It would
be indicated to conduct similar studies for OPV.
We have found in several studies that subsequent
boosting with a live vaccine with a beneﬁcial effect
enhanced the beneﬁcial effect. The present analysis sug-
gests that different live vaccines with beneﬁcial effects
may interact with each other. Both MV and OPV have
been reported to have particularly strong protective
effects against lower respiratory infection,26 27 33 so
maybe the vaccines boost similar responses.
Although OPV0 and OPV campaigns may have
lowered mortality, campaign-OPV given before and after
administration of early MV at 4.5 months of age may
have increased mortality in the early two-dose MV
group, at least relative to the one-dose MV group
(table 3). We have had a similar experience of negative
interaction between interventions with NVAS which
neutralised the beneﬁcial effect of early two-dose MV
(table 4).3 11 Children who received the two-dose
regime and no NVAS had a 50% reduction in mortality
between 4.5 and 36 months. However, if they had been
randomised to receive NVAS, there was no effect from
receiving MV at 4.5 months. NVAS apparently reduced
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mortality in the one-dose group and increased it in the
two-dose group. This appears to be parallel to what hap-
pened to children who received campaign-OPV both
before and after enrolment in the present trial. Both
experiences suggest that interfering immune training
may have occurred in the ﬁrst months of life.
All children had received the three doses of OPV with
DTP before enrolment into the MV trial. Hence, it is a
challenge to explain why additional doses of OPV before
enrolment should affect the immune system and result
in a modiﬁcation of the response to early MV. It is an
additional challenge that it seemingly makes a differ-
ence whether this additional dose is given at birth as
OPV0 (which primes for a beneﬁcial response to early
MV) or campaign-OPV (which primes for a negative
response to early MV). One speculation could be that
OPV has different NSEs depending on the age and the
type of vaccine it is given with: OPV0 was often given at
birth, into the sterile gut, where it may affect the micro-
biome, and it was given with BCG. Campaign-OPV-
before-enrolment, on the other hand, was given alone,
and campaign-OPV seems to be beneﬁcial in its own
right (A Andersen, et al. National immunisation cam-
paigns with OPV reduce all-cause mortality: a natural
experiment within seven randomised trials. (In review)).
Campaign-OPV-after-enrolment was often given with VAS
and may have had yet other NSEs.
Implications: An increasing number of studies suggest that
OPV may be associated with beneﬁcial NSEs. With the
beneﬁcial NSEs of OPV0 and of campaign-OPV for chil-
dren who received the currently recommended vaccin-
ation schedule, it is possible that the repeated
campaigns with OPV have been a driving force in the
decline towards Millennium Development Goal 4
(MDG4) which has been going on in the past 15–
20 years (A Andersen, et al. National immunisation cam-
paigns with OPV reduce all-cause mortality: a natural
experiment within seven randomised trials. (In review)).
This needs to be explored now before OPV is stopped,
phased out or replaced by IPV. We have previously docu-
mented that IPV was associated with signiﬁcantly higher
female than male mortality in randomised trials in
which IPV was given as a comparator vaccine.34 Hence,
stopping OPV campaigns or replacing OPV with IPV
could lead to changes in mortality level.35 During the
period we are studying here, it was triple OPV which was
given in the campaigns. This vaccine was discontinued
in April 2016 to be replaced by bivalent OPV.
Table 4 Possible modifiers of the effect of early measles vaccination on mortality
Epidemiological observations Comparable biological data
Early OPV enhances the beneficial effect of early MV at
4–5 months of age (this paper)
Cross-stimulation has been shown to enhance immunological
responses, eg, early BCG primes for a stronger specific
immune response to hepatitis B vaccine (HBV) and OPV
vaccinations.6 7 On the other hand, we have also observed
that OPV given with BCG at birth reduces the specific immune
response to BCG. Effect of cross-stimulation on mortality has
not been studied.
Campaign-OPV-before-early MV reduces the beneficial
effect of early MV (this paper). Campaign-OPV may have
both reduced the mortality level in the 1-dose group and
increased the mortality rate slightly in the 2-dose MV group,
resulting in an overall elimination of the differential
(beneficial) effect of early MV (this paper).
The sequence or combination of early life vaccines, including
BCG, OPV, DTP, and HBV, often have an impact on
subsequent mortality.19 28 29 The underlying biological
mechanisms have not been studied.
Campaign-OPV-after-early MV (and usually after a second
dose of MV) following previous OPV before early MV
reduces the benefit of early MV by reducing mortality more
strongly in the 1-dose MV group or by increasing mortality in
the 2-dose group (this paper).
Several studies have shown that re-exposure to the same
antigen enhances the beneficial effect, eg, BCG, MV and
Vaccinia. Such beneficial boosting effects of OPV could be
more pronounced in the 1-dose group which had more to gain.
The underlying biological mechanisms have not been studied.
Presence of maternal measles antibodies enhances the
beneficial effect of early MV at 4.5 months of age20
This has been shown in animal studies but has not been
studied for other human pathogens.30
Neonatal vitamin A (NVAS) reduced the beneficial effect of
early MV at 4.5 months of age3. As with campaign-OPV,
NVAS may have both reduced the mortality level in the
one-dose group and increased the mortality rate slightly in
the 2-dose MV group, resulting in an overall elimination of
the differential (beneficial) effect of early MV.11
In vitro studies have shown that vitamin A induces innate
immune tolerance. Providing vitamin A can abrogate the innate
immune training induced by BCG.31
DTP after early MV associated with increased mortality for
females19
Numerous studies have shown that DTP and other inactivated
vaccines administered after MV reduced or removed the
beneficial non-specific effects of MV.19 29 The underlying
biological mechanisms have not been studied.
DTP, diphtheria-tetanus-pertussis; MV, measles vaccine; NVAS, neonatal vitamin A supplementation; OPV, oral polio vaccine.
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Subsequent analyses have shown no signiﬁcant differ-
ences in their beneﬁcial effects (A Andersen, et al.
National immunisation campaigns with OPV reduce all-
cause mortality: a natural experiment within seven ran-
domised trials. (In review)).
This study also suggests that campaign-OPV-
before-enrolment interfered with the otherwise beneﬁ-
cial effect of early MV. This negative interaction could
potentially be important in the situations where early
MV is recommended, for example to children with HIV
infection who should receive a ﬁrst dose of MV already
at 6 months of age.
Many interventions which have been recommended
based on RCTs showing a beneﬁcial effect on children
survival, for example, VAS, have turned out to present
different effects in subsequent RCTs. Campaigns with
OPV, MV, VAS or NVAS may be behind the situations in
which effects change. This phenomenon of interactions
between interventions with an early priming effect on
the immune system needs to be understood better to be
able to predict whether new interventions will have
beneﬁcial or deleterious effects on overall health. It is
worth emphasising that among children who received
OPV0 and BCG in the ﬁrst weeks of life, received no
NVAS, received no campaign-OPV and received no DTP
after MV, early MV was associated with 85% (53% to
96%) reduction in mortality between 4.5 and 36 months
of age (data not shown). This effect was not in relation
to unvaccinated control children but compared with the
current strategy of one dose of MV at 9 months of age.
Hence, we might be able to do much more to reduce
mortality if we fully understood early immune training
and used this knowledge.
The speciﬁc disease perspective in global public
health has generated the idea that once we have eradi-
cated a disease, we can remove the preventive interven-
tion and save resources. To the extent interventions have
beneﬁcial immune training effects, this may be a disas-
trous misunderstanding. Since both polio and measles
are targeted for eradication within the next 10–20 years,
there are good reasons to further explore the beneﬁcial
NSEs of OPV and MV and possibly be able to induce
them in other ways.
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